AstraZeneca Plans to Launch 100 New Medicines in China by 2029
AstraZeneca’s EVP Sharon Barr reveals the company’s plans to launch 100 new medicines in China over the next five years, highlighting mutual interests with Chinese collaborators.
AstraZeneca
Read More
AstraZeneca Invests $700M in Qingdao, Elevating Innovation on the Chinese Mainland
AstraZeneca commits $700 million to a new inhaled medicines facility in Qingdao, positioning the Chinese mainland as a key innovation hub.
AstraZeneca CEO Optimistic About China’s Economic Growth and Supply Chain
AstraZeneca CEO Pascal Soriot expresses strong confidence in China’s supply chain efficiency and its pivotal role in the company’s global operations at the 2024 Boao Forum for Asia.
The Chinese Mainland Set to Lead the Next Wave of Biopharmaceutical Innovation
Pascal Soriot, CEO of AstraZeneca, highlights the Chinese mainland’s pivotal role in driving biopharmaceutical innovation at the Boao Forum 2024.
AstraZeneca Boosts Presence in the Chinese Mainland with Major Pharma Investments
AstraZeneca CEO Pascal Soriot discusses the company’s strategic investments in the Chinese mainland’s pharmaceutical sector during an interview with CGTN’s Zheng Junfeng.